Showing results (1711-1720 of 1,725) with videos related to

Sort By:
Pageof 173
Cell Genomics|February 21, 2026
Hi-C for genome-wide detection of enhancer-hijacking rearrangements in routine lymphoid cancer biopsiesJamin Wu, Shih-Chun A Chu, Jang Cho, et al.
Elife|July 25, 2018
Antibiotic-induced acceleration of type 1 diabetes alters maturation of innate intestinal immunityXue-Song Zhang, Jackie Li, Kimberly A Krautkramer, et al.
Nature Communications|March 31, 2026
Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized phase 2 trialLi-Ting Liu, Xue-Song Sun, Ting-Ting Quan, et al.
JAMA Oncology|June 18, 2025
Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical TrialShan-Shan Guo, Xiao-Yun Li, Li-Ting Liu, et al.
American Heart Journal|June 28, 2024
PCSK9 inhibitor added to high-intensity statin therapy to prevent cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention: a randomized, double- blind, placebo-controlled, multicenter SHAWN studyZhi-Ming Wu, Jing Kan, Fei Ye, et al.
The Lancet. Oncology|November 10, 2024
Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trialSai-Lan Liu, Xiao-Yun Li, Jin-Hao Yang, et al.
The Lancet. Oncology|June 8, 2023
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trialLi-Ting Liu, Huai Liu, Ying Huang, et al.
The Lancet. Digital Health|July 1, 2023
Multimodal recurrence scoring system for prediction of clear cell renal cell carcinoma outcome: a discovery and validation studyCheng-Peng Gui, Yu-Hang Chen, Hong-Wei Zhao, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 1, 2025
[18F] Fluorodeoxyglucose positron emission tomography/computed tomography scan and liquid biopsy at 12 weeks posttreatment for surveillance of locoregionally advanced nasopharyngeal carcinomaLi-Ting Liu, Zhen-Chong Yang, Jia-Rui He, et al.
Eclinicalmedicine|November 17, 2025
Epstein-Barr virus DNA-guided chemoradiotherapy for patients with low-risk locoregionally advanced nasopharyngeal carcinoma: a secondary 5-year follow-up analysis of an open-label, randomised controlled, phase 2 non-inferiority trialYu-Chen Li, Xiao-Yun Li, Kai-Qi Lan, et al.
Pageof 173